---
title: "kfsyscc-of-Enfortumab vedotin"
slug: "kfsyscc-of-enfortumab-vedotin"
date: "2023-11-26"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自: [[Enfortumab vedotin]]

# kfsyscc-of-Enfortumab vedotin

- Padcev powder for infusion 30 mg/24kg enfortumab vedotin/vial 備思復凍晶注射劑 IENFO3 (臨採)
- 常用劑量
  - Urothelial cancer, locally advanced or metastatic, combination therapy:
  - IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1 and 8 every 21 days (in combination with pembrolizumab) until disease progression or unacceptable toxicity
  - Urothelial cancer, locally advanced or metastatic, single-agent treatment:
  - IV: 1.25 mg/kg (maximum dose: 125 mg) on days 1, 8, and 15 every 28 days until disease progression or unacceptable toxicity
- 劑量調整
  - Dosage in renal impairment: No dosage adjustment necessary.
  - Dosage in hepatic impairment: Moderate to severe impairment (total bilirubin >1.5 times ULN and any AST): Avoid enfortumab vedotin use.
- 自費價格 30055/24kg = 90000/72kg
